Скачайте изображение (превью) выбрав качество

320x180 480x360 640x480 1280x720

Watch on Radcliffe Cardiology: *1o0av21*_ga*MTMwMzM0NDE5OC4xNjQ0ODQ4MDk3*_ga_T874FCJ3LG*MTY2NTM5MDE2Mi4zMzAuMS4xNjY1MzkwOTEyLjAuMC4w

Dr Steven Nissen (Cleveland Clinic, US) joins us to discuss the findings of the SURMOUNT-MMO trial. This study aimed to evaluate the effect of tirzepatide in type II diabetes patients who have obesity, or are overweight.

Questions:
1. What was the rationale behind this study?
2. What is the mechanism of action of Tirzepatide?
3. What was the study design?
4. What were the main outcomes?
5. How should these findings impact practice?
6. What are your take-home messages?

Recorded Remotely from Cleveland, 2022.

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Чтобы скачать видео "EASD 2022: SURMOUNT-MMO: Tirzepatide in Obese Type II Diabetes Patients | Dr Steven Nissen" передвинте ползунок вправо